The interest in, and use of liquid biopsy in precision medicine therapeutic development has increased dramatically in the past decade.

A growing body of research demonstrates the broad utility of liquid biopsy for a range of applications, from elucidating and confirming mechanism of action to stratifying patients and monitoring response to treatment. In this white paper, we explore the opportunities and challenges associated with liquid biopsy as well as methods for cell-free DNA and circulating tumor cell (CTC) analysis. 

Key points covered include: 

• Potential advantages of liquid biopsy over solid tumor biopsy 
• Genomic profiling of cell-free DNA 
• Approaches for CTC isolation to enable CTC analysis 
• How CTC-based liquid biopsy can be leveraged in all phases of clinical development